SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-18-015027
Filing Date
2018-03-26
Accepted
2018-03-26 17:04:01
Documents
5
Effectiveness Date
2018-03-26

Document Format Files

Seq Description Document Type Size
1 FORM 8-K s002111x6_8k.htm DEFA14A 22263
2 EXHIBIT 99.1 s002111x6_ex99-1.htm EX-99.1 48900
3 EXHIBIT 99.2 s002111x6_ex99-2.htm EX-99.2 4616
4 EXHIBIT 99.1 IMAGE 001 s002111x6_ex99-1image001.jpg GRAPHIC 92305
5 EXHIBIT 99.1 IMAGE 002 s002111x6_ex99-1image002.jpg GRAPHIC 9242
  Complete submission text file 0001140361-18-015027.txt   216928
Mailing Address 2855 GAZELLE CT CARLSBAD CA 92010
Business Address 55 CAMBRIDGE PARKWAY SUITE 100 CAMBRIDGE MA 02142 760-603-2732
AKCEA THERAPEUTICS, INC. (Filer) CIK: 0001662524 (see all company filings)

IRS No.: 472608175 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38137 | Film No.: 18713379
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1